ATRION CORP

2024 Q3 Form 10-Q Financial Statement

#000165495424010185 Filed on August 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.59M
YoY Change 223.21%
Cash & Equivalents $11.46M
Short-Term Investments $6.124M
Other Short-Term Assets $7.480M
YoY Change 12.94%
Inventory $67.64M
Prepaid Expenses
Receivables $26.56M
Other Receivables $0.00
Total Short-Term Assets $119.3M
YoY Change 2.8%
LONG-TERM ASSETS
Property, Plant & Equipment $122.9M
YoY Change -3.76%
Goodwill $9.730M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments $5.624M
YoY Change -44.79%
Other Assets $1.818M
YoY Change -11.96%
Total Long-Term Assets $141.1M
YoY Change -6.45%
TOTAL ASSETS
Total Short-Term Assets $119.3M
Total Long-Term Assets $141.1M
Total Assets $260.4M
YoY Change -2.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $16.31M
YoY Change 4.88%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.54M
YoY Change 6.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities $3.944M
YoY Change -30.15%
Total Long-Term Liabilities $3.944M
YoY Change -30.15%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.54M
Total Long-Term Liabilities $3.944M
Total Liabilities $21.48M
YoY Change -2.69%
SHAREHOLDERS EQUITY
Retained Earnings $377.2M
YoY Change -0.78%
Common Stock $342.0K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $206.6M
YoY Change 0.02%
Treasury Stock Shares
Shareholders Equity $238.9M
YoY Change
Total Liabilities & Shareholders Equity $260.4M
YoY Change -2.43%

Cashflow Statement

Concept 2024 Q3 2024 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
17462000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
27075000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
82307000 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1761 shares
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
9875000 usd
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
18003000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
67641000 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1761 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1763 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
240916000 usd
us-gaap Revenues
Revenues
96107000 usd
us-gaap Revenues
Revenues
83831000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.73
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.70
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
37770000 usd
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
15245000 usd
us-gaap Inventory Write Down
InventoryWriteDown
2300000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
402000 usd
us-gaap Net Income Loss
NetIncomeLoss
3194000 usd
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1762 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.81
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.81
CY2023Q2 us-gaap Revenues
Revenues
43838000 usd
CY2024Q2 us-gaap Revenues
Revenues
48773000 usd
CY2023Q2 us-gaap Revenues
Revenues
43838000 usd
dei Entity Central Index Key
EntityCentralIndexKey
0000701288
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3420000 shares
atri Treasury Stock Purchased Value
TreasuryStockPurchasedValue
0 usd
CY2024Q2 atri Shares Surrendered In Stock Transactions Amount
SharesSurrenderedInStockTransactionsAmount
0 usd
CY2024Q2 atri Treasury Stock Purchased Value
TreasuryStockPurchasedValue
0 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-32982
dei Entity Registrant Name
EntityRegistrantName
Atrion Corporation
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
63-0821819
dei Entity Address Address Line1
EntityAddressAddressLine1
One Allentown Parkway
dei Entity Address City Or Town
EntityAddressCityOrTown
Allen
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75002
dei City Area Code
CityAreaCode
972
dei Local Phone Number
LocalPhoneNumber
390-9800
dei Security12b Title
Security12bTitle
Common stock, Par Value $0.10 per share
dei Trading Symbol
TradingSymbol
ATRI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1759954 shares
CY2024Q2 us-gaap Revenues
Revenues
48773000 usd
CY2023Q2 us-gaap Revenues
Revenues
43838000 usd
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
32926000 usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
26584000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
67909000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
51496000 usd
CY2024Q2 us-gaap Gross Profit
GrossProfit
15847000 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
17254000 usd
us-gaap Gross Profit
GrossProfit
28198000 usd
us-gaap Gross Profit
GrossProfit
32335000 usd
CY2024Q2 us-gaap Selling Expense
SellingExpense
2714000 usd
CY2023Q2 us-gaap Selling Expense
SellingExpense
2317000 usd
us-gaap Selling Expense
SellingExpense
5486000 usd
us-gaap Selling Expense
SellingExpense
5045000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11279000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5951000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16066000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12205000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1320000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1607000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2970000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3236000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
15313000 usd
us-gaap Operating Expenses
OperatingExpenses
24522000 usd
us-gaap Operating Expenses
OperatingExpenses
20486000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
534000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
7379000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
3676000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
11849000 usd
CY2024Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
388000 usd
CY2023Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
127000 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
544000 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
367000 usd
CY2024Q2 us-gaap Gain Loss On Sale Of Other Investments
GainLossOnSaleOfOtherInvestments
-542000 usd
CY2023Q2 us-gaap Gain Loss On Sale Of Other Investments
GainLossOnSaleOfOtherInvestments
98000 usd
us-gaap Gain Loss On Sale Of Other Investments
GainLossOnSaleOfOtherInvestments
-651000 usd
us-gaap Gain Loss On Sale Of Other Investments
GainLossOnSaleOfOtherInvestments
-623000 usd
CY2024Q2 us-gaap Other Income
OtherIncome
23000 usd
CY2023Q2 us-gaap Other Income
OtherIncome
29000 usd
us-gaap Other Income
OtherIncome
37000 usd
us-gaap Other Income
OtherIncome
39000 usd
CY2024Q2 us-gaap Interest Expense
InterestExpense
0 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
27000 usd
us-gaap Interest Expense
InterestExpense
0 usd
us-gaap Interest Expense
InterestExpense
27000 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-131000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
227000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-70000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-244000 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
403000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7606000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3606000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11605000 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1043000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-412000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1557000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
402000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
6563000 usd
us-gaap Net Income Loss
NetIncomeLoss
3194000 usd
us-gaap Net Income Loss
NetIncomeLoss
10048000 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.73
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.81
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.71
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1761 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1760 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1761 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1761 shares
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.23
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.81
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.70
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1763 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1761 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1762 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1762 shares
CY2024Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
2.20
CY2023Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
2.15
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
4.40
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
4.30
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11462000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3565000 usd
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
6124000 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
2691000 usd
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
26555000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
23029000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
67641000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
82307000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7480000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3173000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
119262000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
114765000 usd
CY2024Q2 us-gaap Long Term Investments
LongTermInvestments
5624000 usd
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
8165000 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
286224000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
286445000 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
163319000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
161098000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
122905000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
125347000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1015000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1072000 usd
CY2024Q2 us-gaap Goodwill
Goodwill
9730000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
9730000 usd
CY2024Q2 us-gaap Other Assets
OtherAssets
1818000 usd
CY2023Q4 us-gaap Other Assets
OtherAssets
1746000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
12563000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
12548000 usd
CY2024Q2 us-gaap Assets
Assets
260354000 usd
CY2023Q4 us-gaap Assets
Assets
260825000 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
16314000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
12515000 usd
CY2024Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
1223000 usd
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
106000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
17537000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12621000 usd
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3944000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5315000 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3420000 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
342000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
342000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
67911000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
67331000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
377176000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
381754000 usd
CY2024Q2 us-gaap Treasury Stock Preferred Shares
TreasuryStockPreferredShares
1660000 shares
CY2023Q4 us-gaap Treasury Stock Preferred Shares
TreasuryStockPreferredShares
1660000 shares
CY2024Q2 us-gaap Treasury Stock Value
TreasuryStockValue
206556000 usd
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
206538000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
238873000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
242889000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
260354000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
260825000 usd
us-gaap Profit Loss
ProfitLoss
3194000 usd
us-gaap Profit Loss
ProfitLoss
10048000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
7959000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
7264000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-560000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-1249000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
722000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1039000 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
500000 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
623000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
33000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
111000 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
11782000 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
17614000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3526000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-258000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-14666000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
14459000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
4307000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
3142000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
72000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-200000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3631000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2637000 usd
us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
1117000 usd
us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
799000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-812000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-177000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
22479000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3730000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5460000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16702000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
5570000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
5644000 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
327000 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
131000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
3885000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
19503000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6818000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2712000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1650000 usd
atri Shares Witholding For Employees
SharesWitholdingForEmployees
-20000 usd
atri Shares Witholding For Employees
SharesWitholdingForEmployees
-57000 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
7744000 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
7568000 usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0 usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
14540000 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
10705000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-7764000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5440000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
7897000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4422000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3565000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4731000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11462000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
309000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2234000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2853000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
238641000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
6563000 usd
CY2023Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
575000 usd
CY2023Q2 atri Shares Surrendered In Stock Transactions Amount
SharesSurrenderedInStockTransactionsAmount
-35000 usd
CY2023Q2 atri Treasury Stock Purchased Value
TreasuryStockPurchasedValue
-1037000 usd
CY2023Q2 us-gaap Dividends
Dividends
3791000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
240916000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
241923000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
402000 usd
CY2024Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
439000 usd
CY2024Q2 us-gaap Dividends
Dividends
3891000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
238873000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
239541000 usd
us-gaap Net Income Loss
NetIncomeLoss
10048000 usd
us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
612000 usd
atri Shares Surrendered In Stock Transactions Amount
SharesSurrenderedInStockTransactionsAmount
-57000 usd
atri Treasury Stock Purchased Value
TreasuryStockPurchasedValue
-1650000 usd
us-gaap Dividends
Dividends
7578000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
242889000 usd
us-gaap Net Income Loss
NetIncomeLoss
3194000 usd
us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
582000 usd
atri Shares Surrendered In Stock Transactions Amount
SharesSurrenderedInStockTransactionsAmount
-20000 usd
us-gaap Dividends
Dividends
7772000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
238873000 usd
us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>(1) Basis of Presentation</strong> </p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;">The accompanying unaudited condensed consolidated financial statements of Atrion Corporation and its subsidiaries (collectively referred to herein as “Atrion,” the “Company,” “we,” “our,” or “us”) have been prepared in accordance with accounting principles generally accepted in the United States (US GAAP) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and notes required by US GAAP for complete financial statements. In the opinion of management, these statements include all normal and recurring adjustments necessary to present a fair statement of our consolidated results of operations, financial position, and cash flows. Operating results for any interim period are not necessarily indicative of the results that may be expected for the full year. Preparation of the Company’s financial statements in conformity with US GAAP requires management to make estimates and assumptions that can have a significant impact on our revenue, operating income, and net income, as well as on the value of certain assets and liabilities on our consolidated balance sheets. We base our assumptions, judgments, and estimates on historical experience and various other factors that we believe to be reasonable under the circumstances. We are not aware of any specific event or circumstance that would require updates to our estimates or judgments or require us to revise the carrying value of our assets or liabilities as of August 8, 2024, the date of issuance of this Quarterly Report on Form 10-Q. However, these estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions. At least quarterly, we evaluate our assumptions, judgments, and estimates, and make changes as we deem necessary.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;">This Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 ("2023 Form 10-K").</p>
atri Merger Agreement Description
MergerAgreementDescription
i) $460.00 and (ii) the aggregate number of shares of our common stock underlying or denominated by such stock unit (with respect to performance-based stock units, vesting at target), less applicable taxes and authorized deductions
CY2024Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
34393000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
6563000 usd
us-gaap Net Income Loss
NetIncomeLoss
10048000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1760 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1761 shares
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1761 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1762 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.73
CY2024Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
11452000 usd
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
3563000 usd
CY2024Q2 us-gaap Customer Deposits Current
CustomerDepositsCurrent
10000 usd
CY2023Q4 us-gaap Customer Deposits Current
CustomerDepositsCurrent
2000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11462000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3565000 usd
CY2024Q2 atri Bonds Held To Maturity
BondsHeldToMaturity
5944000 usd
CY2023Q4 atri Bonds Held To Maturity
BondsHeldToMaturity
2552000 usd
CY2024Q2 atri Available For Sales Securities Equity Securities Current
AvailableForSalesSecuritiesEquitySecuritiesCurrent
180000 usd
CY2023Q4 atri Available For Sales Securities Equity Securities Current
AvailableForSalesSecuritiesEquitySecuritiesCurrent
139000 usd
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
6124000 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
2691000 usd
CY2024Q2 atri Available For Sales Securities Equity Securities Noncurrent
AvailableForSalesSecuritiesEquitySecuritiesNoncurrent
3809000 usd
CY2023Q4 atri Available For Sales Securities Equity Securities Noncurrent
AvailableForSalesSecuritiesEquitySecuritiesNoncurrent
4354000 usd
CY2024Q2 atri Available For Sales Securities
AvailableForSalesSecurities
1773000 usd
CY2023Q4 atri Available For Sales Securities
AvailableForSalesSecurities
236000 usd
CY2024Q2 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
42000 usd
CY2023Q4 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
3575000 usd
CY2024Q2 us-gaap Long Term Investments
LongTermInvestments
5624000 usd
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
8165000 usd
CY2024Q2 atri Cash Cash Equivalents And Short Term And Long Term Investments
CashCashEquivalentsAndShortTermAndLongTermInvestments
23210000 usd
CY2023Q4 atri Cash Cash Equivalents And Short Term And Long Term Investments
CashCashEquivalentsAndShortTermAndLongTermInvestments
14421000 usd
CY2024Q2 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
5986000 usd
atri Securities Maturity Description
SecuritiesMaturityDescription
the length of time to maturity for the bonds we held ranged from 1 to 18 months
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P15Y8M1D
us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
13840000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
12825000 usd
CY2023 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P15Y8M1D
CY2023 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
13840000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
12768000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
112000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
112000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
108000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
108000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
108000 usd
CY2024Q2 us-gaap Revenues
Revenues
48773000 usd
us-gaap Revenues
Revenues
96107000 usd
us-gaap Revenues
Revenues
83831000 usd
us-gaap Revenues
Revenues
96107000 usd
us-gaap Revenues
Revenues
83831000 usd

Files In Submission

Name View Source Status
0001654954-24-010185-index-headers.html Edgar Link pending
0001654954-24-010185-index.html Edgar Link pending
0001654954-24-010185.txt Edgar Link pending
0001654954-24-010185-xbrl.zip Edgar Link pending
atri-20240630.xsd Edgar Link pending
atri_10q.htm Edgar Link pending
atri_ex311.htm Edgar Link pending
atri_ex312.htm Edgar Link pending
atri_ex321.htm Edgar Link pending
atri_ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
atri-20240630_def.xml Edgar Link unprocessable
atri-20240630_lab.xml Edgar Link unprocessable
atri-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
atri_10q_htm.xml Edgar Link completed
atri-20240630_cal.xml Edgar Link unprocessable